Previous infection with other types of coronaviruses may lessen severity of COVID-19

Being previously infected with a coronaviruses that cause the "common cold" may decrease the severity of severe acute respiratory syndrome coronavirus (SARS-CoV-2) infections, according to results of a new study. Led by researchers at Boston Medical Center and Boston University School of Medicine, the study also demonstrates that the immunity built up from previous non-SARS-CoV-2 coronavirus infections does not prevent individuals from getting COVID-19. Published in the Journal of Clinical Investigation, the findings provide important insight into the immune response against SARS-CoV-2, which could have significant implications on COVID-19 vaccine development.

The COVID-19 pandemic has led to more than 200,000 deaths in the US, and more than one million globally. There is a growing body of research looking into specific ways that the SARS-CoV-2 virus impacts different populations, including why some people are infected and are asymptomatic, as well as what increases ones mortality as a result of infection. There are a number of vaccines under development in order to determine what type of vaccine (mRNA, viral vector) will be most effective at preventing SARS-CoV-2 infections.

While SARS-CoV-2 is a relatively new pathogen, there are many other types of coronaviruses that are endemic in humans and can cause the "common cold" and pneumonia. These coronaviruses share some genetic sequences with SARS-CoV-2, and the immune responses from these coronaviruses can cross-react against SARS-CoV-2.

In this study, the researchers looked at electronic medical record data from individuals who had a respiratory panel test (CRP-PCR) result between May 18, 2015 and March 11, 2020. The CRP-PCR detects diverse respiratory pathogens including the endemic "common cold" coronaviruses. They also examined data from individuals who were tested for SARS-CoV-2 between March 12, 2020 and June 12, 2020. After adjusting for age, gender, body mass index, and diabetes mellitus diagnosis, COVID-19 hospitalized patients who had a previous positive CRP-PCR test result for a coronoavirus had significantly lower odds of being admitted to the intensive care unit (ICU), and lower trending odds of requiring mechanical ventilation during COVID. The probability of survival was also significantly higher in COVID-19 hospitalized patients with a previous positive test result for a "common cold" coronoavirus. However, a previous positive test result for a coronavirus did not prevent someone from getting infected with SARS-CoV-2.

"Our results show that people with evidence of a previous infection from a "common cold" coronavirus have less severe COVID-19 symptoms," said Manish Sagar, MD, an infectious diseases physician and researcher at Boston Medical Center, associate professor of medicine and microbiology at Boston University School of Medicine and the study's co-corresponding author. Another interesting finding, the authors note, is that immunity may prevent disease (COVID-19) in ways that are different from preventing infection by SARS-CoV-2. This is demonstrated by the fact that the patient groups had similar likelihoods of infection but differing likelihoods of ending up in the ICU or dying.

"People are routinely infected with coronaviruses that are different from SARS-CoV-2, and these study results could help identify patients at lower and greater risk of developing complications after being infected with SARS-CoV-2," said Joseph Mizgerd, ScD, professor of medicine, microbiology, and biochemistry at Boston University School of Medicine who is the study's co-corresponding author. "We hope that this study can be the springboard for identifying the types of immune responses for not necessarily preventing SARS-CoV-2 infection but rather limiting the damage from COVID-19."

Manish Sagar, Katherine Reifler, Michael Rossi, Nancy S Miller, Pranay Sinha, Laura White, Joseph P Mizgerd,
Recent endemic coronavirus infection is associated with less severe COVID-19.
J Clin Invest. 2020. 10.1172/JCI143380.

Most Popular Now

COVID-19 vaccine AZD1222 clinical trials resumed i…

Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the UK following confirmation by the Medicines Health Regulatory Authority (MHRA)...

CureVac expected to receive up to 252 million euro…

CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) in clinical trials...

Pfizer and BioNTech propose expansion of pivotal C…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) announced that they have submitted an amended protocol to the U.S. Food and Drug Administration to expand the enrol...

Sinovac reports preliminary Phase I/II results of …

Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announced that the inactivated COVID-19 vaccin...

Lilly and Amgen announce manufacturing collaborati…

Eli Lilly and Company (NYSE:LLY) and Amgen (NASDAQ:AMGN) today announced a global antibody manufacturing collaboration to significantly increase the supply capacity avail...

Pfizer and BioNTech announce data from preclinical…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced preliminary preclinical data in mouse and non-human primate models from their BNT162b2 mRNA-based v...

Sanofi and GSK will provide up to 300 million dose…

Sanofi and GSK finalized and signed today an Advanced purchase agreement with the European Commission (EC) for the supply of up to 300 million doses of a COVID-19 vaccine...

COVID-19 study links strict social distancing to m…

Using public transportation, visiting a place of worship, or otherwise traveling from the home is associated with a significantly higher likelihood of testing positive wi...

T cells take the lead in controlling SARS-CoV-2 an…

Ever since SARS-CoV-2 first appeared, researchers have been trying to understand whether sometimes the immune system does more harm than good during the acute phase of CO...

Genome analyses track SARS-CoV-2's early introduct…

SARS-CoV-2 arrived in Washington State somewhere between late January and early February 2020, sparking rapid community transmission of the virus that went undetected for...

Statement on AstraZeneca Oxford SARS-CoV-2 vaccine…

As part of the ongoing randomised, controlled clinical trials of the AstraZeneca Oxford coronavirus vaccine, AZD1222, a standard review process has been triggered, leadin...

Designed antiviral proteins inhibit SARS-CoV-2 in …

Computer-designed small proteins have now been shown to protect lab-grown human cells from SARS-CoV-2, the coronavirus that causes COVID-19. In the experiments, the le...